Scarica l'app Stockscreener
4.30
2.14%
0.09
Dopo l'orario di chiusura:
4.23
-0.07
-1.63%
Precedente Chiudi:
$4.21
Aprire:
$4.15
Volume 24 ore:
136.36K
Relative Volume:
1.43
Capitalizzazione di mercato:
$61.12M
Reddito:
$134.00K
Utile/perdita netta:
$-33.51M
Rapporto P/E:
-1.3406
EPS:
-3.2074
Flusso di cassa netto:
$-18.15M
1 W Prestazione:
-1.15%
1M Prestazione:
-3.15%
6M Prestazione:
-21.53%
1 anno Prestazione:
-26.81%
Intervallo 1D:
$4.12
$4.4899
Intervallo di 1 settimana:
$4.09
$4.70
Portata 52W:
$3.25
$13.50
Clene Inc Stock (CLNN) Company Profile
Nome
Clene Inc
Settore
Industria
Telefono
801-676-9695
Indirizzo
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
4.30 | 61.12M | 134.00K | -33.51M | -18.15M | -3.2074 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-10-04 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-07-18 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-02 | Iniziato | Canaccord Genuity | Buy |
| 2021-09-28 | Iniziato | Oppenheimer | Outperform |
Clene Inc Borsa (CLNN) Ultime notizie
Clene to Present at Upcoming Investor Conferences - manilatimes.net
Investors can meet Clene management in New York or online through Sept. 30 - Stock Titan
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA - Investing News Network
Clene raises $4 million from insiders to fund operations By Investing.com - Investing.com Australia
Clene raises $4 million from insiders to fund operations - Investing.com
A $4 million raise is expected to carry an ALS biotech past a potential FDA decision - Stock Titan
Insider-linked LLC acquires new Clene (CLNN) shares - Stock Titan
Clene (CLNN) Surged +1.55%: Here's What Analysts Are Saying 2026-09-17High Yield Stocks - careplusvn.com
Form 8K Clene Inc. For: 16 September By Investing.com - Investing.com Nigeria
Clene Raises $4 Million in Registered Direct Offering to Existing Holders at $3.28 - TradingView
Insiders back new funding round at Clene Inc. (CLNN) to support lead drug filing - Stock Titan
Clene Announces $4 Million Registered Direct Offering - Investing News Network
Clene prices $4M registered direct offering at $3.28 per share - Investing.com India
A biotech's $4 million stock offering is expected to fund operations into 2027 - Stock Titan
Insiders Could Have Profited By Holding onto Clene Shares Despite 15% Drop - simplywall.st
CLNN Stock Falls After Roth Labels Accelerated Approval For ALS Drug A ‘Long Shot’ - stocktwits.com
Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing By Investing.com - Investing.com Canada
Clene to Present at Upcoming September Investor Conferences - Investing News Network
Two investor conferences in New York will hear from Clene this month - Stock Titan
CLENE Q2 BASIC EPS USD -1.08 - Moomoo
Clene (CLNN) Financial Results: EPS Prints Above Forecast in the Latest Reading; Trading Move: Shares Finish 1.14% Down at the CloseNext Quarter Guidance - vinanet.vn
Analysts’ Top Consumer Goods Picks: Kimberly Clark (KMB), Clene (CLNN) - The Globe and Mail
Clene (CLNN) Outlook: Adds 4.30% to Close at $4.37 at the Close; Price Context: the Near-Term Reference Band Stretches From $4.15 to $4.59 under the Current SnapshotUnusual Put Volume - dars.gov.et
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses - MarketBeat
Clene at Emerging Growth Conference: FDA path takes shape for ALS drug - Investing.com
CLNN: CNM-Au8 shows strong survival and functional benefits in ALS, with NDA submission imminent - TradingView
Clene (CLNN) Move: Climbs 0.49% to $4.11 on the Day; Technical Setup: $3.90 and $4.32 Define the Nearby Reference Levels for the Current SessionVWAP Deviation - vinanet.vn
JonesTrading Maintains Clene(CLNN.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream - Investing News Network
HC Wainwright Issues Negative Estimate for Clene Earnings - MarketBeat
CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment - Stocktwits
Clene(CLNN) Stock Options Chain | Quotes & News - Moomoo
Clene to Present at the Emerging Growth Conference - Investing News Network
Clene stock holds at buy as H.C. Wainwright keeps $31 target By Investing.com - Investing.com Australia
Clene schedules a 3:10 p.m. webcast—what will it cover? - Stock Titan
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com
Clene (NASDAQ:CLNN): Why Is Evidence And Funding in Focus Today? - Kalkine Media
Clene (NASDAQ:CLNN): Why Is Clinical Evidence in Focus Today? - Kalkine Media
CLNN Looks 375.9% Overvalued on GF Value™ - GuruFocus
Clene earnings missed by $0.75, revenue topped estimates - Investing.com
Clene (NASDAQ:CLNN) Announces Quarterly Earnings Results, Misses Estimates By $0.71 EPS - MarketBeat
Clene Releases Q2 2026 Financial Results - AlphaStreet
Vivo Opportunity entities disclose 9.99% Clene Inc. (CLNN) stake via warrants - Stock Titan
Clene Inc. (CLNN) grants 3,195 stock options to director Matthew Kiernan - Stock Titan
Clene Inc. (CLNN) grants 4,872 stock options to director Alison Mosca - Stock Titan
Clene Inc. (CLNN) grants director Arjun Desai 3,674 options at $4.19 strike - Stock Titan
Clene Inc. (CLNN) director receives 6,230 stock options at $4.19 strike - Stock Titan
Clene Inc. (CLNN) awards director Shalom Jacobovitz 4,752 stock options at $4.19 - Stock Titan
Clene Inc. (CLNN) director receives 3,514 stock options vesting immediately at $4.19 - Stock Titan
Clene Inc. (CLNN) director granted 3,514 stock options at $4.19 strike - Stock Titan
Clene Q2 FY26 net loss widens 81% to $13.42 million - Bitget
Clene Inc Azioni (CLNN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):